{‘She possesses little qualifications’: this American scientific establishment girds for Dr. Høeg's appointment at the FDA.

While America proceeds with unprecedented changes to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning Covid vaccines throughout the global health crisis and has zeroed in on possible deaths following COVID-19 vaccination in her short position at the Food and Drug Administration.

Planned Changes to Childhood Immunization Program

Agency leaders were set to unveil sweeping changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US at odds with a large portion of the world with insufficient data for public health gain. This reveal has been postponed until the new year.

In place of the top vaccines chief, Høeg is listed to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US to become more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been standard for former directors of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who led CBER have had.”

CDER has an immense portfolio at the agency, Woodcock pointed out.

“The public just pays attention on the innovative therapies, but the generic program approves a multitude of generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those have to be looked after,” Dr. Woodcock noted. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the job, which supervises in excess of 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” Woodcock concluded.

Official Statement and Disputed Policies

Regarding questions about Høeg’s qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a press secretary stated that the “inquiries stem from inaccurate premises”.

“Her resume aligns with the responsibilities of her position,” the representative stated, pointing to the months Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that allegedly worried her predecessors. “By what process are these therapies being picked for this expedited pathway? Who is making the choices?” Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the agency seems to be moving towards laxer regulations of most medications, except for immunizations.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a clearer, if problematic, track record, critics have noted. She authored a analysis using non-validated public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the new administration encompassed changing guidelines for recently developed shots and halting “non-essential” immunizations, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of preventing adolescent males from receiving Covid vaccinations.

“She’s an complete ideologue who starts off with her conclusions and works backwards to fit the science in a extremely deceptive, fraudulent fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|